U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541534) titled 'A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors' on April 08.
Brief Summary: This study is an open-label, first-in-human Phase I clinical study to evaluate the safety, tolerability, PK characteristics, and preliminary antitumor activity of HLX316 in participants with advanced/metastatic solid tumors. The study will consist of 2 parts: a Phase Ia dose-escalation part and a Phase Ib dose-expansion part. Phase Ia and Phase Ib will focus on exploring the preliminary antitumor activity of HLX316 in participants with platinum-resistant ovarian cancer, primary peritoneal cancer, or fallopian tube c...